Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed vs Sunitinib vs Combination in 2nd-Line NSCLC
NCT00698815Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2008
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sunitinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by National Cancer Institute. Primary endpoint: 18 Week Progression-free Survival Rate. Started Apr 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00698815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00698815.